Compare DexCom, Inc. (DXCM) vs KeyCorp (KEY) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

KeyCorp (KEY) trades at $23.30, up 0.34% with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and net income margin improving to 26.05%. Recent corporate developments include a $0.21 dividend declaration and a new $3 billion buyback program representing 12% of market cap, signaling management confidence in capital returns.

With 61% analyst buy ratings and a $29.32 consensus price target suggesting 26% upside, KEY presents a compelling value opportunity. However, investors should monitor the bank's ability to sustain revenue growth above $7 billion and navigate potential interest rate volatility that could impact net interest income margins.